Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company DOV Pharmaceutical has terminated a license agreement with Merck & Co for certain compounds which the firm has been developing.
Subscribe to our email newsletter
DOV said that the drug candidates DOV 21,947 and DOV 216,303, have been terminated by the parties effective December 6, 2006. New Jersey-based DOV said that it will regain all rights to the compounds, which will enable the company to increase its focus on its reuptake inhibitor program.
DOV, which is focused on the development of novel drug candidates for central nervous system disorders, said that there are no payments due to Merck.